3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Glioma
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Fulvestrant
127
Trastuzumab
117
Paclitaxel
113
Letrozole
109
pembrolizumab
81
palbociclib
76
pertuzumab
75
Capecitabine
74
Anastrozole
72
Cyclophosphamide
70
Carboplatin
67
abemaciclib
65
exemestane
63
Tamoxifen
63
ribociclib
61
trastuzumab deruxtecan
57
Specimen Handling
51
Surveys and Questionnaires
50
Radiotherapy
50
Docetaxel
49
Magnetic Resonance Spectroscopy
48
Blood Specimen Collection
42
olaparib
40
Standard of Care
36
Biopsy
33
sacituzumab govitecan
32
130-nm albumin-bound paclitaxel
32
Exercise
30
Doxorubicin
30
eribulin
29
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
gadoterate meglumine
×
1 year
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled